Related Experiment Videos
Behavioral and neurochemical modifications caused by chronic alpha-methylparatyrosine administration
1Istituto di Farmacologia e Farmacognosia, Università di Torino, Italy.
Abstract:
The chronic administration of alpha-methylparatyrosine (AMT) caused a reduction of the noradrenaline levels in the hippocampus (at 150 and 300 mg/kg/day) and in the subcortex (at 30, 150 and 300 mg/kg/day). The acetylcholine levels were reduced in the hippocampus and in the olfactory brain at all the tested doses of AMT. An increase of the Bmax of muscarinic and alpha 1-adrenoceptors was observed at 30 mg/kg/day of AMT; only in the subcortex AMT caused no modification of the density of muscarinic receptors. The degree of increase of the receptors density at 30 mg/kg/day was reduced at the higher doses of AMT. AMT 30 mg/kg/day caused a reduction of the errors in the staircase maze after 20 days of interruption of the daily training. These results might suggest a correlation between the behavioral effect and the increase of density, not only of the adrenoceptors, but also of the muscarinic receptors. It is proposed that the behavioral effects caused by chronic AMT are the consequence of complex neurochemical interactions.
Insights
Chronic alpha-methylparatyrosine (AMT) administration reduced noradrenaline and acetylcholine levels. AMT also altered muscarinic and alpha-1 adrenoceptor density, correlating with improved performance in a staircase maze.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Alpha-methylparatyrosine (AMT) is a tyrosine hydroxylase inhibitor.
- Understanding AMT's neurochemical effects is crucial for its therapeutic applications.
Purpose of the Study:
- To investigate the chronic effects of AMT on neurotransmitter levels and receptor density.
- To explore the correlation between neurochemical changes and behavioral outcomes.
Main Methods:
- Chronic administration of varying doses of AMT (30, 150, 300 mg/kg/day).
- Measurement of noradrenaline and acetylcholine levels in specific brain regions (hippocampus, subcortex, olfactory brain).
- Assessment of muscarinic and alpha-1 adrenoceptor density (Bmax).
- Behavioral testing using a staircase maze.
Main Results:
- AMT reduced noradrenaline levels in the hippocampus and subcortex.
- Acetylcholine levels decreased in the hippocampus and olfactory brain.
- A dose-dependent increase in muscarinic and alpha-1 adrenoceptor density was observed, with a reduction at higher doses.
- AMT at 30 mg/kg/day improved staircase maze performance after training interruption.
Conclusions:
- Chronic AMT administration induces complex neurochemical changes, including neurotransmitter depletion and altered receptor density.
- Behavioral improvements may be linked to increased adrenoceptor and muscarinic receptor density.
- These findings suggest a correlation between neurochemical modulation and cognitive function enhancement by AMT.